NTRK2 and acute myeloid leukemia: Taylor et al. (2018) also evaluated larotrectinib’s activity on Trk fusions found in patients with AML, histiocytosis, and multiple myeloma in a cell-based proliferation assay and on an AML patient-derived xenograft containing ETV6–NTRK2 cells.